Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15789757 | 0.83 | CDK1 (0.50) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL9153899 | 0.77 | CDK1 (0.44) | HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL852593 | 0.75 | HSP90AB1 (0.41) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL17040218 | 0.74 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL24474430 | 0.73 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL9663203 | 0.73 | HDAC6 (0.47) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL17226007 | 0.73 | CDK1 (0.55) | — | |
| SCHEMBL764036 | 0.73 | CDK1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL27983442 | 0.71 | CDK1 (0.59) | HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL9226296 | 0.71 | HSP90AB1 (0.38) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3539546-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20130090299-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-8318701-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-7871991-B2 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | GILEAD SCIENCES, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2258376-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090202470-A1 | Phosphonate Analogs of Hiv Inhibitor Compounds | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1778251-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006110157-A9 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES INC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | GILEAD SCIENCES, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2006110157-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202470-A1 | Phosphonate Analogs of Hiv Inhibitor Compounds | PIK3CA, TYMP, ITPA | HSP90AB1 3339/4885HSP90AA1 4003/4885HDAC6 2679/4885 |
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | INPP5D, INPPL1, MTAP | HSP90AB1 4556/4885HSP90AA1 4582/4885HDAC6 4781/4885 |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | HSP90AB1 3339/4885HSP90AA1 4003/4885HDAC6 2679/4885 |
| US-20130090299-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | HSP90AB1 3339/4885HSP90AA1 4003/4885HDAC6 2679/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | HSP90AB1 3339/4885HSP90AA1 4003/4885HDAC6 2679/4885 |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | HSP90AB1 3339/4885HSP90AA1 4003/4885HDAC6 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.